Tag: GlobeNewswire

Board of Directors authorizes repurchase of up to $30 million of the Company’s common stock

LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) — XMax Inc. (NASDAQ: XMAX) (“XMax” or the “Company”), a distributor of contemporary furniture and artificial intelligence software and platform-based service provider, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million in aggregate purchase price of its outstanding common stock, par value $0.001 per share. Shares may be repurchased only at prices below $5.50 per share.

The program will begin on a date to be determined (the “Commencement Date”) after the Company has (i) publicly released its financial results for the fiscal quarter ended September 30, 2026 by press release (“Earnings Release”), (ii) publicly disclosed any material nonpublic information, and (iii) engaged a broker-dealer for the program. No repurchases will be made before the Commencement Date, and the program will expire three months after it.

Repurchases are expected to be made from time to time through open-market purchases, which may include purchases under a trading plan intended to satisfy Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are intended to be made in accordance with Rule 10b-18 under the Exchange Act and other applicable legal requirements.

The timing, manner, price (subject to the $5.50 per share limit) and amount of any repurchases will be determined by the Company’s management based on its evaluation of market conditions, the trading price of the Company’s common stock, liquidity and capital requirements, legal requirements, and other factors. The program does not obligate the Company to repurchase any particular number of shares, and it may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund repurchases with its existing cash and cash equivalents.

“The Board’s authorization of this share repurchase program reflects our confidence in XMax’s long-term strategy and our commitment to creating value for shareholders,” said Andy Lu, Chief Executive Officer of XMax. “As we continue to develop our artificial intelligence software and platform-based services alongside our contemporary furniture business, we intend to take a disciplined approach to capital allocation, balancing investment in the growth of the business with returns to our shareholders.”

About XMax Inc.

Headquartered in Commerce, California, XMax Inc. (NASDAQ: XMAX), formerly known as Nova LifeStyle, Inc., is a diversified company engaged in the design, sourcing, and distribution of contemporary furniture, as well as the development of artificial intelligence technologies and applications. The Company operates through an established global network of suppliers, distributors, and e-commerce channels, serving a broad customer base. The Company has expanded into artificial intelligence technologies, including AI software and platform-based services through its wholly owned subsidiaries XMax AI Inc. and Elonx AI Holdings PTE. LTD., to support future growth. By leveraging emerging technologies, the Company aims to drive diversification and long-term value creation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding the share repurchase program, the expected timing of its commencement and of the Earnings Release, and the manner, timing, amount and funding of any repurchases. These statements are based on current expectations, assumptions and analyses made by us in light of our experience and our perception of trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances, and are subject to risks and uncertainties that may cause actual results to differ materially, including changes in the trading price of the Company’s common stock, market conditions, the Company’s financial condition, liquidity and capital requirements, legal and regulatory requirements, and the other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory,” “focus,” “work to,” “attempt,” “pursue,” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. XMax Inc. undertakes no obligation to update any forward-looking statements except as required by law.

Investor Relations Contact

ICR LLC
XMaxIR@icrinc.com

Nuclear News’ recognition highlights Waples’ technical leadership and contributions to advancing innovative nuclear waste disposal solutions

PLANO, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (OTCQB: DBHL) (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that Matt Waples, the Company’s Director of Engineering, has been named to Nuclear News’ 2026 “40 Under 40” list, recognizing emerging leaders whose technical expertise and innovation are helping shape the future of the nuclear industry. Published by the American Nuclear Society, Nuclear News’ annual “40 Under 40” program celebrates young professionals making meaningful contributions to nuclear science, technology, and industry advancement.

“Matt exemplifies the technical excellence and leadership needed to address one of the nuclear industry’s most important challenges,” said Rod Baltzer, CEO of Deep Isolation. “His ability to translate complex engineering challenges into practical solutions has been instrumental to our progress. We are incredibly proud to see his contributions recognized among the next generation of nuclear industry leaders.”

“It is an honor to be recognized alongside so many talented professionals working to advance nuclear energy,” said Waples. “Developing practical solutions for nuclear waste disposal requires collaboration, rigorous engineering and a commitment to long-term safety. I am proud to be part of a team helping move these technologies toward real-world application.”

Since joining Deep Isolation in 2022, Matt Waples has played a central role in advancing the Company’s deep borehole disposal technology, bringing expertise across engineering design, regulatory analysis, safety, operations and project management. His contributions have supported key research and development initiatives aimed at establishing practical, scalable pathways for the long-term disposal of spent nuclear fuel and high-level radioactive waste.

Waples played a key role in Deep Isolation’s U.S. Department of Energy-funded ARPA-E UPWARDS project, leading regulatory analysis and waste acceptance criteria development. His leadership extends to the ARPA-E SAVANT project, where his work on disposal canister materials and supply chains contributed to a paper receiving a “Superior” recognition at the 2025 Waste Management Symposia. Waples has also supported international initiatives and collaborative research through the International Atomic Energy Agency and the OECD Nuclear Energy Agency’s WISARD project.

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. Deep Isolation’s solution is designed to offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact
Sophie McCallum
media@deepisolation.com

Investor Contact
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards; our failure to manage our growth effectively or to execute our business plan; a failure to sustain and expand relationships with governmental entities and strategic partners; failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law. ”

Additional information concerning the factors above and other factors can be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026, subsequent quarterly reports on Form 10-Q filed with the SEC, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation Nuclear at InvestorRelations@deepisolation.com.

Naples, Italy and Hamilton, Bermuda, Nov. 03, 2026 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games and growing its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”), today announced a landmark moment for Savoia, which has advanced to the quarter-finals of the Coppa Italia for the first time in its 118-year history. Goals from Pasquale Riccardi and Matteo Polizzi secured a 2-0 victory over Sorrento at home on October 27, delivering a significant milestone for the Club. The Coppa Italia is an annual Italian domestic knock out competition played by 60 teams. The Copa Italia Serie C winner qualifies for the promotion playoff round for potential advancement to Serie B.

Three Matches, Three Wins

The achievement was built one round at a time. Savoia began with a 2-1 win away at Casertana on August 14, followed by a 3-0 win away at Catania on September 2, before the decisive evening against Sorrento at home. Across the three matches, the Club scored seven goals and conceded only one.

Next Up: The Defending Champs

The quarter-final brings a prestigious test: on December 8, Savoia travels to face defending champions and current cup holder Potenza. The Club views the fixture as a further source of pride and an incentive to keep improving.

October in the League

The cup success crowned a month that was also encouraging in the Serie C league. Savoia drew 0-0 away at Monopoli on October 3, defeated Inter U23 2-1 on October 10, and drew 1-1 with Cosenza on October 24, collecting valuable points along the way. The month’s only setback was a 4-0 defeat to Cerignola on October 18.

Savoia defeated Sorrento 2-0 at home.

History is Made and the Work Continues

“Reaching the quarter-finals of the Coppa Italia for the first time is an emotional moment that we share with the entire Savoia family. For 118 years, generations of supporters have cherished these colors and passed their passion down through their families. Adding a new chapter to that history fills us with pride and brings a great sense of responsibility. Credit goes to the players, the coaching staff and everyone who works on this project every day. We dedicate this historic achievement to our supporters, with the ambition of giving them even more to celebrate. October also leaves us with a positive league record. The victory over Inter U23 and the draws against Monopoli and Cosenza are important results; the defeat at Cerignola remains a match we must learn from. We are fully on track with our plan and continue to work with confidence, humility and ambition. Achieving this historic milestone gives us even greater motivation to keep moving forward.”

• General Manager and Chief Operating Officer of Savoia, Nazario Matachione.

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company’s three mobile games in development include Regalia Cards (card game), Palazzo Chronicles (match-3 castle and garden-building game) and Viva Verdi (trading card game). The Company is also actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachment

• THE ROYALAND COMPANY LTD.

• CETLAM sponsors this Phase Ib pilot study in European patients with newly diagnosed AML in subpopulations with poor responses to standard-of-care treatment. Thirteen hospitals will participate
• CETLAM is a Spanish cooperative clinical research group bringing together specialists from leading hospitals dedicated to advancing treatment research in acute leukemias and myelodysplastic syndromes

• This additional clinical study complements Oryzon’s planned ALICE-3 Phase III program in the U.S., and will provide operational experience relevant to the program’s future European arm

MADRID and CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that VIVALDI, a Phase Ib pilot study sponsored by CETLAM — Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásicas, has been authorized in Spain. The study will evaluate iadademstat in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia (ND-AML) belonging to subgroups associated with suboptimal responses to current standard-of-care treatment.

CETLAM is a Spanish cooperative clinical research group that brings together specialists from leading hospitals in the research and treatment of acute myeloid leukemia and myelodysplastic syndromes. The group has more than three decades of experience in developing treatment protocols and conducting collaborative clinical research. Oryzon is collaborating with CETLAM and supplying iadademstat for the study.

“VIVALDI expands our clinical investigation of iadademstat in AML in Spain through our collaboration with CETLAM’s prestigious hematology network. In parallel, we are advancing preparations for ALICE-3, our registrational Phase III trial, building on the strong clinical data from ALICE-2 to be presented soon at ASH,” said Carlos Buesa, Chief Executive Officer of Oryzon.

“Our development strategy prioritizes patients with substantial unmet need, including those with TP53 or RAS pathway mutations,” Buesa added. “VIVALDI findings in these populations may also provide complementary insights to inform future regulatory discussions. The study will also help us plan the future European arm of ALICE-3, taking into account the operational differences between conducting the trial in Europe and the United States.”

Dr. Jordi Esteve, President of CETLAM’s Board and Principal Investigator of VIVALDI at Hospital Clínic de Barcelona, said: “We are excited to bring, for the first time, this promising investigational combination to Spanish patients with TP53-mutated AML and other adverse-risk forms of the disease, building on the encouraging early clinical results and favorable tolerability observed in the U.S. ALICE-2 study. VIVALDI will also enable correlative studies to explore the biology underlying treatment response and deepen our understanding of LSD1 inhibition in these particularly difficult-to-treat leukemias.”

Dr. Olga Salamero of Vall d’Hebron University Hospital and co-Principal Investigator in VIVALDI, added: “In the earlier ALICE-1 study, led by our Vall d’Hebron University Hospital/VHIO AML team, iadademstat combined with azacitidine showed encouraging activity, including in patients with particularly poor prognoses, as the TP53+ patients where we saw a remarkable improvement in overall survival. Those findings, published in The Lancet Haematology, together with the emerging ALICE-2 results with the triplet combination, provide a strong scientific rationale for continued investigation through VIVALDI.”

Oryzon is preparing ALICE-3 as a potentially registrational Phase III study of iadademstat in combination with venetoclax and azacitidine in first-line AML, with initiation planned in 2027, subject to regulatory agreement and financing. The Company expects to present final ALICE-2 data at the 2026 American Society of Hematology (ASH) Annual Meeting. The final design of ALICE-3 remains subject to regulatory discussions and review of emerging clinical evidence.

Public information on VIVALDI is available in the Clinical Trials Information System (CTIS) under EU trial number 2026-527464-32-00.

About Oryzon
Founded in 2000 and headquartered in Barcelona, Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology. Oryzon’s team comprises highly experienced pharmaceutical professionals based in Barcelona, Boston, and New Jersey. The Company has an advanced clinical portfolio built around two LSD1 inhibitors: iadademstat, its oncology/hematology program, which is being evaluated in several ongoing Phase I and II studies and has demonstrated strong preliminary clinical activity in acute myeloid leukemia (AML), including a 100% overall response rate (ORR) in first-line AML; and vafidemstat, its lead CNS program, which is Phase III–ready in borderline personality disorder (BPD) and in a Phase IIb study in schizophrenia. In addition, Oryzon is advancing a broader epigenetics pipeline targeting other mechanisms, including HDAC6, for which the Company has nominated ORY-4001 as a clinical candidate for potential development in Charcot–Marie–Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders. The Company also operates a robust platform for biomarker identification and target validation across malignant and neurological diseases. For more information, visit www.oryzon.com

About Iadademstat
Iadademstat (ORY-1001) is an oral, highly selective inhibitor of the epigenetic enzyme LSD1, with potent differentiating effect in hematologic cancers. Iadademstat has shown encouraging safety and strong clinical activity in combination with azacitidine in a Phase IIa trial in elder patients with 1L acute myeloid leukemia (AML) (ALICE trial). Iadademstat is currently being evaluated in combination with azacitidine and venetoclax in 1L AML in the ALICE-2 trial, an investigator-initiated study (IIS) led by OHSU, and in combination with gilteritinib in the company-sponsored Phase Ib FRIDA trial in relapsed/refractory FLT3-mutant AML, with highly encouraging preliminary safety and efficacy data in both trials reported at EHA-2026: 100% overall response rate (ORR) and 89% composite complete remission rate (CRc), with 78% strict CR in 1L AML, and 67% CRc in R/R FLT3-mut AML. Subject to positive final data in the ALICE-2 study, the company has announced plans to conduct a potentially registrational study in 1L AML. Additional studies in hematologic malignancies include an IIS in myelodysplastic syndrome (MDS) and National Cancer Institute (NCI)-sponsored trials in myeloproliferative neoplasms and 1L AML conducted under the Cooperative Research and Development Agreement (CRADA) between Oryzon and the NCI. Beyond hematological cancers, iadademstat is being evaluated in extensive stage small cell lung cancer (ED-SCLC) in a Phase I/II randomized trial in 1L in combination with immune checkpoint inhibition (ICI) sponsored by NCI and led by the Memorial Sloan Kettering Cancer Center, and an IIS trial in combination with ICI and radiotherapy. Oryzon has also expanded iadademstat into non-oncological hematology indications, with ongoing trials in sickle cell disease and essential thrombocythemia. Iadademstat has orphan drug designation for AML in the US and EU and for SCLC in the US.

FORWARD-LOOKING STATEMENTS  
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration. 

Spain	Oryzon	IR & Media, Europe & US
Patricia Cobo/Mario Cordera	Emili Torrell	Sandya von der Weid
Atrevia	Chief BD Officer	LifeSci Advisors, LLC
+34 91 564 07 25  +34 673 33 97 65	+34 93 515 1313	+41 78 680 05 38
pcobo@atrevia.com  mcordera@atrevia.com	etorrell@oryzon.com	svonderweid@lifesciadvisors.com

PETAH-TIKVA, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) — Global-e Online Ltd. (Nasdaq: GLBE), ), the leading global e-commerce enablement platform powering the world’s most iconic brands, today announced it will report financial results for the third quarter ended September 30, 2026, before market open on Wednesday, November 18, 2026.

Global-e management will host a conference call to review its financial results and outlook.

Date:	Wednesday, November 18, 2026
Time:	8:00 AM ET
United States/Canada Toll Free:	+1-800-717-1738
International Toll:	+1-646-307-1865

Please join the call 5-10 minutes prior to the scheduled start time, to avoid a delay in connecting. A live webcast will be available in the Investor Relations section of Global-e’s website at https://investors.global-e.com/news-events/events-presentations

A replay of the webcast will be available in the Investor Relations section of Global-e’s website at https://investors.global-e.com/news-events/events-presentations approximately two hours after the conclusion of the call.

About Global-e Online Ltd.

Global-e (Nasdaq: GLBE) is the world’s leading platform enabling and accelerating global, Direct-To-Consumer e-commerce. The chosen partner of over 1,500 brands and retailers across North America, EMEA and APAC, Global-e makes selling internationally as simple as selling domestically. The company enables merchants to increase the conversion of international traffic into sales by offering online shoppers in over 200 destinations worldwide a seamless, localized shopping experience. Global-e’s end-to-end e-commerce solutions combine best-in-class localization capabilities, big-data best-practice business intelligence models, streamlined international logistics and vast global e-commerce experience, enabling international shoppers to buy seamlessly online and retailers to sell to, and from, anywhere in the world. For more information, please visit: www.global-e.com.

Investor Contacts:
Alan Katz
Investor Relations
Global-e
alan.katz@global-e.com

Press Contact:
Sarah Small
Headline Media
sarah@headline.media
+1 (914) 336-4718

LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 9:30 a.m. ET.

A live webcast of the presentation can be accessed in the “IR Events and Presentations” section of CalciMedica’s IR website. A replay of the webcast will be archived on the Company’s website for 90 days.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company’s pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora™, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in more than 350 patients and is being developed for pulmonary hypertension and acute pancreatitis, including a planned Phase 1b proof-of-concept trial in PH and a planned Phase 2b trial in acute pancreatitis. CM5480 is also being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027. For more information, please visit www.calcimedica.com.

Investor Relations Contact
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Students are now using Kaltura’s Agentic Learning & Enablement platform for personalized STEM learning, combining conversational AI avatar tutors, interactive practice and insights for teachers

New York, New York, Nov. 03, 2026 (GLOBE NEWSWIRE) — Kaltura (Nasdaq: KLTR), the Agentic Digital Experience company, today announced that Israel’s Ministry of Education has selected Kaltura as a technology provider for its 720 initiative, a national program to advance personalized learning in K–12 schools. Following the completion of teacher training and onboarding, classroom use of Kaltura’s Agentic Learning & Enablement platform is now underway in an initial, one-year pilot across 20 schools serving approximately 2,000 students. 

The 720 initiative’s broader goal is to expand AI-powered personalized learning across schools, grade levels and subjects throughout Israel’s K–12 education system. Its pilot deployments are intended to lay the groundwork for that expansion by combining pedagogy, artificial intelligence, professional development for educators and learning data. The program aims to tailor learning to each student’s strengths, challenges, pace and goals, while helping teachers identify learning gaps, adapt instruction and focus on mentoring and individual guidance. 

Within this broader initiative, Kaltura’s initial pilot implementation focuses on seventh- and eighth-grade students studying STEM subjects – mathematics and science – during the 2026–2027 academic year, with English and other language studies planned as the next phase. The platform brings together conversational AI avatar tutors, personalized learning paths, interactive practice, assessment and progress tracking, supporting an ongoing learning journey within regular classroom instruction. 

Personalized learning with conversational avatars and Dynamic UI 

Kaltura’s real-time conversational AI avatar tutors help students work through curriculum material, ask questions, practice concepts and receive guidance at their own pace. The classroom experience is available in Hebrew and Arabic, supporting personalized instruction across the participating schools. 

Alongside the avatar conversation, Kaltura’s Dynamic UI capabilities provide visual explanations, infographics, quizzes and interactive learning activities. The platform adapts explanations and practice to each student’s needs and progress, combining conversation with visual and interactive experiences to support understanding. 

Teachers receive a classroom-wide view of learning activity and individual progress through dedicated dashboards. These insights help educators identify concepts that require further attention, understand where students encounter difficulties and plan follow-up instruction. The platform supports teachers in guiding the learning process while giving students access to individual assistance during practice. 

“Being selected by the Ministry and bringing our platform into classrooms serving thousands of students is an important commercial milestone for Kaltura,” said Ron Yekutiel, Co-Founder, Chairman, President, and CEO of Kaltura. “We are bringing together conversational avatars, personalized learning paths, interactive practice and progress tracking to support each student’s learning journey, while giving teachers visibility into where their guidance can make a difference. This initiative also demonstrates how working with education systems can help us reach many schools through a coordinated program – a model we plan to develop with additional ministries and partner channels.” 

Expanding through education systems and partner channels 

The Ministry-led initiative illustrates how Kaltura can reach and serve multiple schools through a coordinated education program. Kaltura plans to build on this approach by pursuing relationships with ministries of education and education systems in additional countries, while developing further partner channels for its learning and enablement offerings. These relationships are intended to extend the company’s reach across K–12 education, higher education and enterprise learning. 

The classroom deployment also advances Kaltura’s broader Agentic Learning & Enablement strategy: combining conversational interaction, personalized learning paths and progress measurement across different learning environments. Beyond schools, the company sees applications in university teaching and learning, employee onboarding and professional development, partner training and customer education. 

The initiative builds on Kaltura’s established work with educational institutions and enterprises. Kaltura’s customer base includes more than 40% of U.S. R1 research universities and 30 U.S. Fortune 100 companies. Its technologies support teaching, training, communications and digital engagement through video learning, virtual classrooms, enterprise video and integrations with learning management systems. The classroom pilot extends that experience into integrated learning journeys that bring together personalized tutoring, interactive practice and progress measurement. 

A video about Kaltura’s classroom deployment is available here. 
A demonstration of Kaltura’s Agentic Learning & Enablement platform is available here.

About Kaltura 

Kaltura’s mission is to power rich, agentic digital experiences across organizational journeys for customers, employees, learners, and audiences. Its platform combines intelligent content creation, enterprise-grade content management and intelligence, and multimodal conversational engagement capabilities. Kaltura serves leading enterprises, financial institutions, educational institutions, media and telecom providers, and other organizations worldwide. For more information, visit www.kaltura.com. 

CONTACT: Mira Marcus, PR 
Mira.marcus@kaltura.com 
pr.team@kaltura.com 

• Presentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN with mixed phenotype from the Phase 1 clinical trial
• Presentation at ISA on Nov. 18 to include up to four years of follow-up data in patients with ATTRv-PN

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it will present new clinical data at two medical meetings in November. An analysis from the Phase 1 clinical trial of nex-z in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) with mixed phenotype (i.e. cardiac involvement) will be presented at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois. Long-term follow-up in patients with ATTRv-PN from the Phase 1 clinical trial will be presented at the International Society of Amyloidosis 2026 Symposium (ISA), taking place November 15-18 in Montevideo, Uruguay.  

AHA Poster Presentation Details:

• Title: Cardiac Outcomes Following a Single Dose of Nexiguran Ziclumeran in Patients With Transthyretin Amyloidosis With Cardiomyopathy or Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Phase 1 Analysis
  Type and Session: Moderated Digital Poster – Clinical Science Zone 2
  Poster Number: #12
  Date and Time: Monday, November 9, 11:13 a.m. CT
  Presenter: Yousuf Razvi, MBChB BSc, National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, United Kingdom

ISA Poster Presentation Details:

• Title: Long-Term Durability, Outcomes, and Safety of Nexiguran Ziclumeran Gene Editing in Hereditary Transthyretin Amyloidosis With Polyneuropathy
  Type and Session: E-Poster Session 13 – Treatments of ATTR
  Poster Number: #156
  Date and Time: Wednesday, November 18, 10:04 a.m. UYT
  Presenter: Julian Gillmore, M.D., Ph.D., Professor of Medicine, National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, United Kingdom

The presentations will be made available on the Scientific Publications & Presentations page of www.intelliatx.com at the start of each respective session.

About Nex-z
Based on Nobel Prize-winning CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) and/or hereditary ATTR with polyneuropathy (ATTRv-PN). Nex-z is designed to inactivate the TTR gene that encodes for the transthyretin (TTR) protein and is being investigated in MAGNITUDE and MAGNITUDE-2, Phase 3 clinical trials in ATTR-CM and ATTRv-PN, respectively. Nex-z has received an Orphan Drug and RMAT Designation from the U.S. Food and Drug Administration (FDA) and an Orphan Drug Designation (ODD) from the European Commission. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron Pharmaceuticals, Inc.

About Transthyretin (ATTR) Amyloidosis
Transthyretin amyloidosis, or ATTR amyloidosis, is a rare, progressive and fatal disease. Hereditary ATTR (ATTRv) amyloidosis occurs when a person is born with mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity to misfold. These damaged proteins build up as amyloid in the body, causing serious complications in multiple tissues, including the heart, nerves and digestive system. ATTRv amyloidosis predominantly manifests as polyneuropathy (ATTRv-PN), which can lead to nerve damage, or cardiomyopathy (ATTRv-CM), which can lead to heart failure. Some individuals without the genetic mutation produce non-mutated, or wild-type TTR proteins that become unstable over time, misfolding and aggregating in disease-causing amyloid deposits. This condition, called wild-type ATTR (ATTRwt) amyloidosis, primarily affects the heart. There are an estimated 50,000 people worldwide living with ATTRv amyloidosis and between 200,000 and 500,000 people with ATTRwt amyloidosis. Though there are several approved medications that are intended to stabilize TTR protein or slow its production, unmet needs still exist.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com

Product Revenue Grows 19.7%; Mexico Expansion and Footprint Optimization Position Company for Further End-Market Diversification and Growth

COLUMBUS, Ohio, Nov. 03, 2026 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in medium- and heavy-duty truck, powersports, building products, and industrial and utilities industries across the United States, Canada and Mexico today reports financial and operating results for the fiscal periods ended September 30, 2026.

Eric Palomaki, the Company’s President and Chief Executive Officer, said, “Our third quarter results reflect continued progress against our strategic initiatives that will shape our next phase of growth. While the quarter absorbed several one-time start-up costs associated with our Mexico expansion, footprint optimization, and higher external input costs, we achieved key operational milestones that position us for improved performance. Monterrey is now operational, and the two 4,500-ton presses in Matamoros, which many of our investors saw under construction at our recent Investor Day, are on track to come online by year-end, further expanding our capacity and supporting long-term growth.

As highlighted at our September Investor Day, demand trends continued to improve across several of our key markets. Medium- and heavy-duty truck production continued to recover during the quarter, while building products and industrial and utilities end markets remained healthy. Our commercial pipeline continues to strengthen. So far this year, we have secured approximately $30 million in new business awards and see a path to approximately $50 million in new business awards through six major projects currently in our last stage of our sales pipeline funnel. We also continue to expand our position in attractive long-term growth markets, including a significant award for battery energy storage systems. As electrification, grid hardening and increasing power demand drive infrastructure investment, we believe we are well-positioned to capitalize on these opportunities and further diversify our end-market exposure while advancing sustainable long-term growth,” commented Palomaki.

Alex Panda, the Company’s EVP and Chief Financial Officer, said, “Third quarter financial results reflected strong underlying business activity and continued execution of our strategic growth investments.   Product revenue increased nearly 20% year-over-year, driven by improving heavy-duty truck demand, new program launches, and continued strength in our building products and industrial and utilities end markets.   While profitability was impacted by one-time commissioning costs in Monterrey, portfolio footprint optimization activities, and higher external input costs, these investments are supporting additional capacity, improving operating efficiency, and future growth. Additionally, tooling project revenue accounted for a larger portion of sales during the quarter, which impacts our reported margins in the short term but creates recurring demand and revenue.   Gross margin was 14.8% for the quarter and would have been approximately 18.6%, excluding the impact of tooling project revenue mix and Monterrey commissioning charges. Consistent with our outlook discussed at our Investor Day, we continue to expect full-year net sales to be flat to up approximately 5% with gross margins in the 16% to 17% range.

During the quarter, we continued to invest in initiatives that support long-term growth while maintaining financial flexibility.   This included approximately $0.8 million to establish a center of excellence for our hood and battery systems in our Gaffney, South Carolina facility. Consistent with our disciplined capital allocation strategy, we also remained active in our share repurchase program during the quarter and into October,” commented Panda.

Third Quarter 2026 Highlights

• Total net revenues increased 54.4%, comprised Production revenues of $64.8 million and Tooling Project revenue of $25.4 million.
  • Production revenues increased 19.7% year-over-year, mainly due to higher demand from the medium and heavy-duty truck and new program launches.
  • Tooling Project revenue of $25.4 million compared to $4.3 million year-over-year is project-based revenue that is necessary ahead of a customer production cycle.
• Gross margin of $13.4 million, or 14.8% of net revenues, compared to 17.4% of net sales in the prior year third quarter. Excluding the impact of the tooling project margins and Monterrey commissioning charges, gross margin was 18.6%. This year’s gross margins were also pressured by higher raw material input costs, which were offset by favorable fixed operating leverage, operating efficiencies, and a favorable product mix.
• Selling, general, and administrative expenses of $11.8 million, or 13.1% of net revenues, compared to $7.6 million, or 13.0% of net revenues in the prior year third quarter.
  • Third quarter 2026 SG&A expenses included $1.8 million of non-recurring costs associated with the Mexico expansion and footprint optimization costs.
• Operating income of $1.6 million, or 1.8% of net revenues, which includes non-recurring costs above, compared to operating income of $2.6 million, or 4.4% of net revenues for the prior year third quarter.
• Net income of $1.5 million, or $0.17 per diluted share, compared to net income of $1.9 million, or $0.22 per diluted share for the prior year third quarter. Adjusted net income¹ of $2.9 million, or $0.33 per diluted share, compared to $0.24 per diluted share in the prior year period.
• Adjusted EBITDA¹ of $6.4 million, or 7.1% of net revenues, compared to $6.4 million, or 11.0% for the prior year third quarter.

Nine-Month 2026 Highlights

• Total net revenues comprised Production revenue of $183.2 million and Tooling Project revenue of $28.4 million.
  • Production revenues increased 3.6% due entirely to the higher demand in power sports and new program launches.
  • Tooling Project revenue of $28.4 million compared to $22.3 million year-over-year is project-based revenue that is necessary ahead of a customer production cycle.
• Gross margin of $38.1 million, or 18.0% of net revenues, compared to 18.2% of net revenues in the prior year nine-month period.
• Selling, general, and administrative expenses of $33.4 million, or 15.8% of net revenues, compared to $25.6 million, or 12.9% of net revenues.
  • 2026 nine-month period SG&A expenses included $6.6 million of non-recurring costs associated with the Mexico expansion, footprint optimization and severance costs.
• Operating income of $4.6 million, or 2.2% of net revenues, which includes non-recurring costs above, compared to operating income of $10.6 million, or 5.3% of net revenues for the prior year nine-month period.
• Net income of $3.9 million, or $0.45 per diluted share, compared to net income of $8.1 million, or $0.93 per diluted share for the prior year nine-month period. Adjusted net income¹ of $9.4 million, or $1.07 per diluted share.
• Adjusted EBITDA¹ of $21.4 million, or 10.1% of net revenue, compared to $23.1 million, or 11.6% for the prior year nine-month period.

_{¹Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures as defined and reconciled}

2026 Capital Expenditures

The Company’s capital expenditures for the first nine months of 2026 were $19.7 million, including $12.2 million related to the Company’s Mexico expansion project. For the full year 2026, the Company expects capital spending of approximately $28 to $30 million, including approximately $20 million allocated to the Mexico expansion. The Company generated a Return on Capital Employed¹ of 5.0% for the trailing twelve months and 5.1% excluding cash.

Financial Position at September 30, 2026

The Company’s cash and revolving credit facility balance at September 30, 2026, was $5.4 million and $4.8 million, respectively. On July 2, 2026, the Company entered into the third amendment of its 2022 Credit Agreement. This amendment refinanced the Company’s existing term loan and credit facilities. The Company has secured credit facilities in an aggregate principal amount of $100 million, consisting of a $50 million revolving credit facility and a $50 million delayed draw term loan facility at favorable rates compared to the 2022 Credit Agreement.  

Conference Call

The Company will conduct a conference call today at 10:00 a.m. Eastern Time to discuss financial and operating results for the period ending September 30, 2026. To access the call live by phone, dial (844) 881-0134 and ask for the Core Molding Technologies call at least 10 minutes prior to the start time. A telephonic replay will be available through November 10, 2026, by calling (855) 669-9658 and using passcode ID: 1960550#. A webcast of the call will also be available live and for later replay on the Company’s Investor Relations website at www.coremt.com/investor-relations/events-presentations/. 

About Core Molding Technologies, Inc.

Core Molding Technologies is a leading engineered materials company specializing in molded structural products, principally in building products, utilities, transportation and powersports industries across North America. The Company operates in one operating segment as a molder of thermoplastic and thermoset structural products. The Company’s operating segment consists of one reporting unit, Core Molding Technologies. The Company offers customers a wide range of manufacturing processes to fit various program volume and investment requirements. These thermoset processes include compression molding of sheet molding compound (“SMC”), resin transfer molding (“RTM”), liquid molding of dicyclopentadiene (“DCPD”), spray-up and hand-lay-up. The thermoplastic processes include direct long-fiber thermoplastics (“DLFT”) and structural foam and structural web injection molding. Core Molding Technologies serves a wide variety of markets, including the medium and heavy-duty truck, marine, automotive, agriculture, construction, and other commercial products. The demand for Core Molding Technologies’ products is affected by economic conditions in the United States, Mexico, and Canada. Core Molding Technologies’ operations may change proportionately more than revenues from operations.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws that are subject to risks and uncertainties. These statements often include words such as “believe”, “anticipate”, “plan”, “expect”, “intend”, “will”, “should”, “could”, “would”, “project”, “continue”, “likely”, and similar expressions. In particular, this press release may contain forward-looking statements about the Company’s expectations for future periods with respect to its plans to improve financial results, the future of the Company’s end markets. Factors that could cause actual results to differ from those reflected in forward-looking statements relating to our operations and business include: dependence on certain major customers, and potential loss of any major customer due to completion of existing production programs or otherwise; business conditions in the plastics, transportation, power sports, utilities and commercial product industries (including changes in demand for production); the availability and price increases of raw materials; general macroeconomic, social, regulatory and political conditions, including uncertainties surrounding volatility in financial markets; the imposition of new or increased tariffs and the resulting consequences; safety and security conditions in Mexico; costs and other resources related to Core Molding Technologies’ efforts to expand its customer base and grow its business, and provide on-time delivery to customers; the Company’s decision to pursue new products and initiatives to quote and execute manufacturing processes for new business, acquire raw materials, address inflationary pressures, regulatory matters and labor relations; the ability to successfully identify, evaluate and manage potential acquisitions and to benefit from and properly integrate any completed acquisitions; the Company’s financial position or other financial information; inadequate insurance coverage to protect against potential hazards; equipment and machinery failure; product liability and warranty claims; cybersecurity incidents or other similar disruptions; and other risks and uncertainties described in the Company’s filings with the SEC. These statements are based on certain assumptions that the Company has made in light of its experience as well as its perspective on historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from the anticipated results because of certain risks and uncertainties, including those included in the Company’s filings with the SEC. There can be no assurance that statements made in this press release relating to future events will be achieved. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by such cautionary statements.

Company Contact:
Core Molding Technologies, Inc.
Alex Panda
Executive Vice President & Chief Financial Officer
apanda@coremt.com 

Investor Relations Contact:
Three Part Advisors, LLC
Sandy Martin or Steven Hooser
smartin@threepa.com, shooser@threepa.com 

214-616-2207

– Financial Statements Follow –

Core Molding Technologies, Inc.
Consolidated Statements of Operations
(unaudited, in thousands, except share and per share data)
	Three months ended September								Nine months ended September
	2026				2025				2026				2025
Net revenue:
Production	$	64,827			$	54,178			$	183,179			$	176,823
Tooling Project		25,410				4,257				28,370				22,298
Total net revenue		90,237				58,435				211,549				199,121
Total cost of revenue		76,854				48,290				173,460				162,879
Gross margin		13,383				10,145				38,089				36,242
Selling, general and administrative expense		11,793				7,572				33,440				25,616
Operating income		1,590				2,573				4,649				10,626
Other income and expense
Net interest (income) expense		39				34				185				18
Net periodic post-retirement benefit		(117	)			(117	)			(351	)			(344	)
Total other (income) and expense		(78	)			(83	)			(166	)			(326	)
Income before income taxes		1,668				2,656				4,815				10,952
Income tax expense		155				779				914				2,840
Net income	$	1,513			$	1,877			$	3,901			$	8,112
Net income per common share:
Basic	$	0.18			$	0.22			$	0.45			$	0.95
Diluted	$	0.17			$	0.22			$	0.45			$	0.93

Core Molding Technologies, Inc.
Product Revenue by Market
(unaudited, in thousands)
	Three months ended September 30,						Nine months ended September 30,
	2026			2025			2026			2025
Medium and heavy-duty truck	$	28,191		$	19,470		$	71,898		$	80,276
Power sports		13,555			17,548			49,497			45,962
Building products		6,897			5,862			18,387			16,912
Industrial and utilities		7,111			5,851			18,642			17,095
All other		9,073			5,447			24,755			16,578
Net production revenue	$	64,827		$	54,178		$	183,179		$	176,823

Core Molding Technologies, Inc.
Consolidated Balance Sheets
(in thousands)
	As of
	September 30,				As of
	2026				December 31,
	(unaudited)				2025
Assets:
Current assets:
Cash and cash equivalents	$	5,437			$	38,058
Accounts receivable, net		40,643				30,831
Inventories, net		26,693				19,715
Prepaid expenses and other current assets		24,557				14,724
Total current assets		97,330				103,328
Right of use asset		13,775				14,494
Property, plant and equipment, net		97,121				86,940
Goodwill		17,376				17,376
Intangibles, net		2,793				3,479
Other non-current assets		2,565				2,515
Total Assets	$	230,960			$	228,132
Liabilities and Stockholders’ Equity:
Liabilities:
Current liabilities:
Revolving debt	$	4,810			$	—
Current portion of long-term debt						2,075
Accounts payable		29,056				14,924
Contract liabilities		3,231				5,018
Compensation and related benefits		7,871				4,988
Accrued other liabilities		7,316				7,168
Total current liabilities		52,284				34,173
Other non-current liabilities		1,800				1,935
Lease liabilities		12,524				13,113
Long-term debt		—				17,639
Post retirement benefits liability		3,205				3,101
Total Liabilities		69,813				69,961
Stockholders’ Equity:
Common stock		86				85
Paid in capital		49,026				47,503
Accumulated other comprehensive income, net of income taxes		2,749				3,938
Treasury stock		(41,178	)			(39,918	)
Retained earnings		150,464				146,563
Total Stockholders’ Equity		161,147				158,171
Total Liabilities and Stockholders’ Equity	$	230,960			$	228,132

Core Molding Technologies, Inc.
Consolidated Statements of Cash Flows
(unaudited, in thousands)
	Nine months ended September
	2026				2025
Cash flows from operating activities:
Net income	$	3,901			$	8,112
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization		8,743				9,504
Loss on disposal of property, plant and equipment		—				4
Share-based compensation		1,523				1,646
Losses (gain) on foreign currency		(653	)			(285	)
Change in operating assets and liabilities:
Accounts receivable		(9,812	)			(4,759	)
Inventories		(6,978	)			(1,455	)
Prepaid and other assets		(11,039	)			(1,560	)
Accounts payable		15,154				4,060
Accrued and other liabilities		2,865				(744	)
Post retirement benefits liability		(334	)			(357	)
Net cash provided by operating activities		3,370				14,166
Cash flows from investing activities:
Purchase of property, plant and equipment		(19,698	)			(9,305	)
Net cash used in investing activities		(19,698	)			(9,305	)
Cash flows from financing activities:
Gross repayments on revolving line of credit		(18,468	)			—
Gross borrowings on revolving line of credit		23,278				—
Payments for taxes related to net share settlement of equity awards		(612	)			(600	)
Purchase of treasury stock		(648	)			(2,249	)
Payment of principal on term loans		(19,843	)			(1,418	)
Net cash used in financing activities		(16,293	)			(4,267	)
Net change in cash and cash equivalents		(32,621	)			594
Cash and cash equivalents at beginning of period		38,058				41,803
Cash and cash equivalents at end of period	$	5,437			$	42,397
Cash paid for:
Interest	$	492			$	771
Income taxes	$	4,354			$	3,341
Non cash investing activities:
Fixed asset purchases in accounts payable	$	708			$	207

Non-GAAP Financial Measures

This press release contains financial information determined by methods other than in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Core Molding management uses non-GAAP measures in its analysis of the Company’s performance. Investors are encouraged to review the reconciliation of non-GAAP financial measures to the comparable GAAP results available in the accompanying tables.

Reconciliation of Non-GAAP Financial Measures

Adjusted EBITDA represents net income before, as applicable from time to time, (i) interest expense, net, (ii) provision (benefit) for income taxes, (iii) depreciation and amortization of long-lived assets, (iv) share based compensation expense, (v) restructuring and severance costs, and (vi) nonrecurring legal settlement costs and associated legal expenses unrelated to the Company’s core operations. Debt-to-trailing twelve months adjusted EBITDA represents total outstanding debt divided by trailing twelve months Adjusted EBITDA. Free Cash Flow represents net cash (used in) provided by operating activities less purchase of property, plant and equipment. Trailing twelve months return on capital employed represents the trailing twelve months earnings before (i) interest expense, net and (ii) provision (benefit) for income taxes divided by (i) stockholders’ equity and (ii) current and long-term debt. Adjusted Net Income represents net income before severance cost (net of tax).

We present Adjusted EBITDA, Adjusted EBITDA as a percent of net revenue , Free Cash Flow and trailing twelve months Return on Capital Employed because management uses these measures as key performance indicators, and we believe that securities analysts, investors and others use these measures to evaluate companies in our industry. These measures have limitations as analytical tools and should not be considered in isolation or as an alternative to performance measure derived in accordance with GAAP as an indicator of our operating performance. Our calculation of these measures may not be comparable to similarly named measures reported by other companies. The following tables present reconciliations of net income to Adjusted EBITDA, and Cash Flow from Operating Activities to Free Cash Flow, the most directly comparable GAAP measures, and trailing twelve months Return on Capital Employed, for the periods presented:

Core Molding Technologies, Inc.
Net Income to Adjusted EBITDA Reconciliation
(unaudited, in thousands)
	Three months ended September 30,								Nine months ended September 30,
	2026				2025				2026				2025
Net income	$	1,513			$	1,877			$	3,901			$	8,112
Provision for income taxes		155				779				914				2,840
Total other expenses(1)		(78	)			(83	)			(166	)			(326	)
Depreciation and amortization		2,516				3,093				8,614				9,444
Share-based compensation		527				521				1,523				1,646
Severance costs		—				—				1,411				979
Footprint optimization and Mexico Expansion Costs (restructuring)		1,763				220				5,167				420
Adjusted EBITDA	$	6,396			$	6,407			$	21,364			$	23,115
Adjusted EBITDA as a percent of net revenue		7.1	%			11.0	%			10.1	%			11.6	%
(1)Includes net interest expense and non-cash periodic post-retirement benefit cost.

Core Molding Technologies, Inc.
Computation of Debt to Trailing Twelve Months Adjusted EBITDA
(unaudited, in thousands)
		Q4 2025				Q1 2026				Q2 2026				Q3 2026			Trailing Twelve Months
Net income		$	3,083			$	605			$	1,783			$	1,513		$	6,984
Provision for income taxes			642				190				569				155		$	1,556
Total other expenses(1)			(133	)			(31	)			(57	)			(78	)		(299	)
Depreciation and amortization			3,386				3,037				3,061				2,516			12,000
Share-based compensation			142				495				501				527			1,665
Succession plan costs			476				924				487				—			1,887
Footprint optimization and Mexico Expansion Costs (restructuring)		$	—			$	2,102			$	1,302				1,763		$	5,167
Adjusted EBITDA		$	7,596			$	7,322			$	7,646			$	6,396		$	28,960
Total Outstanding Debt as of September 30, 2026																	$	4,810
Debt to Trailing Twelve Months Adjusted EBITDA																		0.17
(1)Includes net interest expense and non-cash periodic post-retirement benefit cost.

Core Molding Technologies, Inc.
Computation of Trailing Twelve Months Return on Capital Employed
(unaudited, in thousands)
		Q4 2025			Q1 2026			Q2 2026			Q3 2026			Trailing Twelve Months
Operating Income		$	3,592		$	764		$	2,295		$	1,590		$	8,241
Equity														$	161,147
Structured Debt														$	4,810
Total Capital Employed														$	165,957
Return on Capital Employed															5.0	%

Core Molding Technologies, Inc.
Computation of Trailing Twelve Months Return on Capital Employed Excluding Cash
(unaudited, in thousands)
		Q4 2025			Q1 2026			Q2 2026			Q3 2026			Trailing Twelve Months
Operating Income		$	3,592		$	764		$	2,295		$	1,590		$	8,241
Equity														$	161,147
Structured Debt														$	4,810
Less Cash														$	(5,437	)
Total Capital Employed, Excluding Cash														$	160,520
Return on Capital Employed, Excluding Cash															5.1	%

Core Molding Technologies, Inc.
Free Cash Flow
Nine Months Ended September 30, 2026 and 2025
(unaudited, in thousands)
	2026				2025
Cash flow provided by operations	$	3,370			$	14,166
Purchase of property, plant and equipment		(19,698	)			(9,305	)
Free cash flow	$	(16,328	)		$	4,861

Core Molding Technologies, Inc.
Adjusted Net Income per Share
(unaudited, in thousands)
	Three months ended September 30,						Nine months ended September 30,
	2026			2025			2026			2025
Net Income	$	1,513		$	1,877		$	3,901		$	8,112
Succession plan costs (net of tax)	$	—					$	1,404		$	773
Mexico expansion and footprint optimization costs (net of tax)	$	1,393		$	174		$	4,072		$	332
Adjusted net income	$	2,906		$	2,051		$	9,377		$	9,217
Weighted average common shares outstanding – basic		8,581,000			8,561,000			8,606,000			8,583,000
Weighted average common and potentially issuable common shares outstanding – diluted		8,727,000			8,688,000			8,758,000			8,709,000
Net income per share – basic	$	0.18		$	0.22		$	0.45		$	0.95
Severance costs (net of tax)		—			—			0.16			0.09
Mexico expansion and footprint optimization costs (net of tax)	$	0.16		$	0.02		$	0.47		$	0.04
Adjusted net income per share – basic	$	0.34		$	0.24		$	1.08		$	1.08
Net income per share – diluted	$	0.17		$	0.22		$	0.45		$	0.93
Severance costs (net of tax)		—			—			0.16			0.09
Footprint optimization costs (net of tax)	$	0.16		$	0.02		$	0.46		$	0.04
Adjusted net income per share – diluted	$	0.33		$	0.24		$	1.07		$	1.06

Hong Kong, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cre8 Enterprise Limited (Nasdaq: CRE) (“Cre8” or the “Company”), a Hong Kong-based integrated financial printing service provider, announced today that its wholly owned subsidiary, Cre8 Incorporation Limited, has completed the acquisition of 100% of the issued shares of Lingxpert Language Services Limited (“LingXpert”), a company incorporated in Hong Kong, which provides translation services in Hong Kong. LingXpert started operations on March 9, 2011. The acquisition is intended to strengthen Cre8’s capacity to support clients on both IPO and non-IPO engagements.

Under the share purchase agreement dated October 19, 2026 (the “Share Purchase Agreement”), the purchase price was US$800,000 in cash, which has been paid in full by bank transfer.  The Closing Date is November 2, 2026.

The acquisition is expected to expand Cre8’s in-house translation capacity and minimize bottlenecks. Cre8 expects to benefit from parallel processing workflows that shorten turnaround times while maintaining stable translation costs.

Moreover, this acquisition is designed to promote resource sharing across logistics, technology, and infrastructure. This approach is expected to reduce overhead costs, optimize capital expenditures, and accelerate project delivery. Pooling financial and human resources is expected to allow Cre8 to scale its operations more effectively.

About Cre8 Enterprise Limited (NASDAQ: CRE)

Cre8 Enterprise Limited provides 24/7 integrated financial printing services to listed companies, IPO applicants, and private companies in the finance and capital market in Hong Kong, and recently expanded into Japan following its acquisition of Upperhand Investment Limited. Its services cover concept creation and artwork design, typesetting, proofreading, translation, printing, binding, logistics arrangement, uploading or making e-submissions of customers’ financial reports and compliance documents, and media placements.

In addition, the Company offers complementary services such as website design, branding and marketing content development. It also provides technology-enabled solutions through its “Cre8IR” platform, which supports the dissemination of announcements, circulars, financial reports, and industry news.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company’s statements regarding the expected benefits of the acquisition of LingXpert, including anticipated operational efficiencies, cost savings and synergies. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to integrate LingXpert’s operations and retain its key personnel and clients, the Company’s ability to realize the anticipated benefits of the acquisition, market conditions, and other factors discussed in the “Risk Factors” section of the Company’s most recent annual report on Form 20-F filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.  

For more information, please contact:

Cre8 Enterprise Limited

Email: ir@cre8corp.com
Phone: +852 3693 2688